Breaking News Instant updates and real-time market news.

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07

Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint

Shares of Ascendis Pharma (ASND) are surging after competitor Versartis (VSAR) announced that its VELOCITY Phase 3 clinical trial of somavaratan, a novel, long-acting form of recombinant human growth hormone for growth hormone deficiency, did not meet its primary endpoint of non-inferiority. Ascendis Pharma develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency. Shares of Ascendis are up 44% to $39.77 while Versartis is plunging 83% to $3.60 per share in after-hours trading.

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND Ascendis Pharma
$27.74

-1.55 (-5.29%)

03/09/17
LEER
03/09/17
DOWNGRADE
Target $30
LEER
Market Perform
Ascendis Pharma downgraded to Market Perform from Outperform at Leerink
Leerink analyst Joseph Schwartz downgraded Ascendis Pharma to Market Perform from Outperform saying the stock's growth spurt looks excessive given limited near-term catalysts. While the analyst continues to expect market entry in 2020 for the lead product, TransCon hGH, and incremental updates for the company's pre-clinical pipeline programs through 2017, he does not see strong reasons for such exuberance to continue over the near-term. Schwartz raised his price target on the shares to $30 from $24.
05/11/17
JPMS
05/11/17
INITIATION
Target $36
JPMS
Overweight
Ascendis Pharma initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Ascendis Pharma with an Overweight rating and $36 price target. The TransCon platform provides a "de-risked approach to developing long-acting therapeutics," the analyst writes.
05/11/17
05/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Methanex (MEOH) initiated with an Underperform at Bernstein. 2. PTC (PTC) initiated with an Outperform at Baird. 3. Pioneer Natural (PXD) assumed with an Overweight at Piper Jaffray. 4. Ascendis Pharma (ASND) initiated with an Overweight at JPMorgan. 5. Control4 (CTRL) initiated with a Hold at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/17
LEER
09/01/17
NO CHANGE
Target $28
LEER
Market Perform
Ascendis shares could move 20% on Versartis data, says Leerink
Leerink analyst Joseph Schwartz believes shares of Ascendis Pharma (ASND) could move up or down 20% on Versartis' (VSAR) somavaratan data in September. The data may have important read-through for Ascendis since it may indicate how much of the long-acting growth hormone market TransCon hGH will need to compete for. The analyst notes his base case scenario has Ascendis shares remaining flat or trading slightly down on somavaratan efficacy, which is "noninferior to daily Genotropin and safety which is acceptable." Schwartz reiterates a Market Perform rating on Ascendis with a $28 price target.
VSAR Versartis
$21.60

-0.25 (-1.14%)

05/05/17
05/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with a Buy at Cleveland Research. 2. Versartis (VSAR) initiated with an Overweight at Cantor. 3. Alder Biopharmaceuticals (ALDR) initiated with a Sell at UBS. 4. Playa Hotels & Resorts (PLYA) initiated with a Neutral at Citi. 5. Coherus Biosciences (CHRS) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/17
PIPR
06/27/17
NO CHANGE
Target $26
PIPR
Overweight
Piper a buyer of Versartis ahead of September data
Piper Jaffray analyst Edward Tenthoff says he's a buyer of Versartis shares ahead of the Phase III Velocity data on somavartan in pediatric growth hormone deficiency expected in September. The analyst is "confident" somavaratan will meet the primary endpoint of non-inferior height velocity at 12 months based on Phase II Vista data that showed consistent HV out to three years. He reiterates an Overweight rating on the shares with a $26 price target.
09/08/17
PIPR
09/08/17
NO CHANGE
Target $26
PIPR
Overweight
Piper says own Versartis into Phase III data later this month
Piper Jaffray analyst Edward Tenthoff recommends owning shares of Versartis into the Phase III Velocity data on somavaratan in pediatric growth hormone deficiency due by the end of September. The analyst continues to expect somavaratan to demonstrate non-inferior height velocity within the 2cm lower confidence interval to daily growth hormone at one year. Even if somavaratan produces numerically lower height velocity to daily growth hormone, this would be a win since less frequent dosing should result in higher real-world compliance and growth, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Versartis with a $26 price target.

TODAY'S FREE FLY STORIES

ELGX

Endologix

$4.38

0.05 (1.15%)

16:02
02/21/18
02/21
16:02
02/21/18
16:02
Earnings
Endologix sees FY18 GAAP EPS (95c)-(89c), may not compare to consensus (50c) »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

HSY

Hershey

$98.47

-1.4314 (-1.43%)

16:01
02/21/18
02/21
16:01
02/21/18
16:01
Earnings
Breaking Earnings news story on Hershey »

Hershey reaffirms FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Apr

ELGX

Endologix

16:01
02/21/18
02/21
16:01
02/21/18
16:01
Earnings
Endologix reports Q4 EPS (17c), consensus (21c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

MMLP

Martin Midstream Partners

$16.05

-0.2 (-1.23%)

15:55
02/21/18
02/21
15:55
02/21/18
15:55
Conference/Events
Martin Midstream Partners to hold a guidance conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    May

SE

Sea Limited

$12.65

0.32 (2.60%)

15:50
02/21/18
02/21
15:50
02/21/18
15:50
Recommendations
Sea Limited analyst commentary  »

Piper Jaffray expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$39.94

-0.08 (-0.20%)

15:34
02/21/18
02/21
15:34
02/21/18
15:34
Options
Avis Budget options imply 12.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VBTX

Veritex

$27.59

-0.48 (-1.71%)

15:33
02/21/18
02/21
15:33
02/21/18
15:33
Conference/Events
Veritex management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 24

    Sep

VBTX

Veritex

$27.59

-0.48 (-1.71%)

15:29
02/21/18
02/21
15:29
02/21/18
15:29
Conference/Events
Veritex management to meet with Stephens »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 24

    Sep

OMER

Omeros

$11.37

0.36 (3.27%)

15:29
02/21/18
02/21
15:29
02/21/18
15:29
Periodicals
Omeros has 'plunging' Omidria sales, 'shaky' balance sheet, Feuerstein says »

Adam Feuerstein of STAT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$8.84

-0.11 (-1.23%)

15:27
02/21/18
02/21
15:27
02/21/18
15:27
Hot Stocks
Telecom Italia says not involved in any anticompetitive behavior »

Regarding today's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KS

KapStone

$34.69

0.14 (0.41%)

15:24
02/21/18
02/21
15:24
02/21/18
15:24
Conference/Events
KapStone management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBK

TriCo Bancshares

$37.24

-0.76 (-2.00%)

15:19
02/21/18
02/21
15:19
02/21/18
15:19
Conference/Events
TriCo Bancshares management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AAOI

Applied Optoelectronics

$33.33

1.34 (4.19%)

15:19
02/21/18
02/21
15:19
02/21/18
15:19
Options
Applied Optoelectronics options imply 22.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

  • 29

    Mar

$NSD

NASDAQ Market Internals

15:17
02/21/18
02/21
15:17
02/21/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

, SPX

S&P 500

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
Technical Take: S&P 500 retests lows of the day »

At time of writing the…

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

, SPX

S&P 500

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
Technical Take: S&P 500 retests lows of the day »

At time of writing the…

SPY

SPDR S&P 500 ETF Trust

$272.87

1.47 (0.54%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/21/18
02/21
15:16
02/21/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABG

Asbury Automotive

$68.25

0.3 (0.44%)

15:15
02/21/18
02/21
15:15
02/21/18
15:15
Conference/Events
Asbury Automotive management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
02/21/18
02/21
15:15
02/21/18
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

WFC

Wells Fargo

$60.35

0.4 (0.67%)

15:10
02/21/18
02/21
15:10
02/21/18
15:10
Options
Notable call write in Wells Fargo »

Notable call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 06

    Mar

  • 07

    Mar

  • 15

    Mar

  • 30

    May

AZN

AstraZeneca

$34.09

0.45 (1.34%)

15:08
02/21/18
02/21
15:08
02/21/18
15:08
Hot Stocks
AstraZeneca announces renewed recommendation, availability of FLUMIST vaccine »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 23

    Apr

P

Pandora

$4.96

-0.375 (-7.04%)

15:04
02/21/18
02/21
15:04
02/21/18
15:04
Options
Pandora options imply 26.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 05

    Mar

BA

Boeing

$358.70

5.35 (1.51%)

, EADSY

Airbus

$29.67

0.08 (0.27%)

15:03
02/21/18
02/21
15:03
02/21/18
15:03
Periodicals
Boeing displaces Airbus at Hawaiian, Leeham News and Comment says »

Boeing (BA) has displaced…

BA

Boeing

$358.70

5.35 (1.51%)

EADSY

Airbus

$29.67

0.08 (0.27%)

HA

Hawaiian Holdings

$37.35

-1.3 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 30

    May

NFLX

Netflix

$278.55

0.03 (0.01%)

15:03
02/21/18
02/21
15:03
02/21/18
15:03
Periodicals
Netflix and indie film makers Duplass Brothers in deal, Variety reports »

Variety reported earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 20

    Mar

MBT

Mobile TeleSystems

$12.66

0.49 (4.03%)

15:00
02/21/18
02/21
15:00
02/21/18
15:00
Options
Call buyers in Mobile TeleSystems as shares reach 52-week highs »

Call buyers in Mobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.